PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ke, Kong, Xiangyi, Li, Yuan, Wang, Zhongzhao, Zhang, Lin, Xuan, Lixue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971753/
https://www.ncbi.nlm.nih.gov/pubmed/35370736
http://dx.doi.org/10.3389/fphar.2022.854967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971753/
https://www.ncbi.nlm.nih.gov/pubmed/35370736
http://dx.doi.org/10.3389/fphar.2022.854967

Ejemplares similares